Cooper Companies reported robust Q3 2024 results, with revenue increasing 8% year-over-year to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.The company demonstrated strong operational performance, with non-GAAP gross margin improving to 67% and non-GAAP operating margin expanding to 26%. Free cash flow for the quarter was $118.5 million. Cooper Companies raised its fiscal year 2024 guidance, now projecting total revenue of $3,892 - $3,913 million, representing organic growth of 8% to 8.5%.President and CEO Al White expressed confidence in the company's momentum and future prospects, citing successful execution of their multi-year growth strategy. The raised guidance reflects the strength of Cooper's business model and positions the company for continued success in the medical device market.

Cooper Companies reported robust Q3 2024 results, with revenue increasing 8% year-over-year to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.The company demonstrated strong operational performance, with non-GAAP gross margin improving to 67% and non-GAAP operating margin expanding to 26%. Free cash flow for the quarter was $118.5 million. Cooper Companies raised its fiscal year 2024 guidance, now projecting total revenue of $3,892 - $3,913 million, representing organic growth of 8% to 8.5%.President and CEO Al White expressed confidence in the company's momentum and future prospects, citing successful execution of their multi-year growth strategy. The raised guidance reflects the strength of Cooper's business model and positions the company for continued success in the medical device market.